Format

Send to

Choose Destination
Curr Treat Options Oncol. 2019 Jun 29;20(8):68. doi: 10.1007/s11864-019-0667-9.

Emerging Role of Genomics and Cell-Free DNA in Breast Cancer.

Author information

1
Department of Medicine, Division of Hematology and Oncology, Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, 710 N Fairbanks Court, Suite 8-250A, Chicago, IL, 60611, USA.
2
Department of Medicine (DAME) - University of Udine, P.le Kolbe 4, 33100, Udine UD, Italy.
3
Department of Medicine, Division of Hematology and Oncology, Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, 710 N Fairbanks Court, Suite 8-250A, Chicago, IL, 60611, USA. massimo.cristofanilli@nm.org.

Abstract

Precision Medicine is gaining momentum as the future gold standard healthcare strategy as it enables treatment optimization and consequently a potential improvement for quality of life and survival. This paradigm shift was possible thanks to new high-throughput genomics technologies, which provide prognostic and predictive information on tumor biology and potential treatment options, as standard pathological procedures are unable to capture both spatial and temporal tumor heterogeneity. As a result of decreasing costs, both solid and liquid-based genomics have an increasingly important role in clinical trials' screening procedures and are gradually being incorporated into clinical practice. Notwithstanding the great potential, its clinical utility is still a matter of debate and clinicians need to be aware of caveats in interpreting resulting data.

KEYWORDS:

Biomarkers; Breast cancer; Circulating tumor DNA; Precision medicine; Translational medicine

PMID:
31256282
DOI:
10.1007/s11864-019-0667-9

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center